Omega-3 Fatty Acid Supplementation and Tear Film Quality in Celiac Patients (OmegaCelDED)
Dry Eye Syndromes, Celiac Disease
About this trial
This is an interventional treatment trial for Dry Eye Syndromes focused on measuring Celiac Disease, Supplementation, Omega-3 Fatty Acids, Dry Eye Syndromes
Eligibility Criteria
Inclusion Criteria: diagnosis of celiac disease signed informed consent form Exclusion Criteria: use of medications for diabetes, hypertension, depression, thyroid disease, allergies, epilepsy, psychosis, glaucoma use of oral contraceptive pills alcoholism or use of alcohol on the day of recruitment menopause eye trauma or surgery in the past 3 months wearing contact lens supplementation with omega-3 fatty acids regardless of the dose used in the past month not understanding Bosnian letter or language Informed consent form not signed
Sites / Locations
- Plava Medical GroupRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
Intervention group 1
Intervention group 2
Control
Supplementation with 2 gel-capsules (each containing 720 mg eicosapentaenoic acid (EPA) and 480 mg docosahexaenoic acid (DHA))
Supplementation with 2 gel-capsules (each containing 320 mg eicosapentaenoic acid (EPA) and 200 mg docosahexaenoic acid (DHA))
Supplementation with 2 gel-capsules (each containing 1000 mg extra virgin olive oil)